LONDON, March 31, 2017 /PRNewswire/ --
Immunovia has announced final top-line data of theIMMray platform from a retrospective study in autoimmune diseases. The study showed that the IMMray biomarker platform could differentiate blood samples from patients with systemic lupus erythematosus (SLE) from other autoimmune diseases with 96% accuracy.
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
We are updating our valuation to SEK151 per share (vs SEK155 per share), mainly for the FY16 net cash position of SEK259m and our expenses forecast. The rest of our assumptions remain the same: we assume a penetration rate of 35% in patients at high risk of pancreatic cancer and 5% in newly diagnosed diabetic patients, targeting total peak sales of c SEK2.1bn in both groups. We look to include SLE in our valuation when Immunovia discloses its plans for this indication.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn http://www.linkedin.com/company/edison-investment-research Twitter http://www.twitter.com/Edison_Inv_Res YouTube http://www.youtube.com/edisonitv Google+ https://plus.google.com/105425025202328783163/posts
For more information please contact: Juan Pedro Serrate Edison Investment Research +44-(0)20-3681-2534 Jonas Peciulis Edison Investment Research +44-(0)20-3077-5728 email@example.com
SOURCE Edison Investment Research
Subscribe to our Free Newsletters!